Related Experiment Video

Updated: Nov 29, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma

Pierangela Sepe1, Alessia Mennitto1, Francesca Corti1

  • 1Genitourinary Cancer Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Immunotargets and Therapy
|November 23, 2020
PubMed

Insights

New immunotherapies and targeted therapies are improving outcomes for metastatic renal cell carcinoma (mRCC). While immune checkpoint inhibitors (ICIs) offer long-lasting responses, research continues to address resistance and enhance treatment strategies for mRCC patients.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has evolved, with angiogenesis inhibitors and immunotherapy now central.
  • Tyrosine kinase inhibitors (TKIs) target angiogenesis, a key driver in renal carcinoma pathogenesis.
  • Immune checkpoint inhibitors (ICIs) have emerged as a significant advancement, particularly in pretreated mRCC.

Purpose of the Study:

  • To review current immunotherapeutic targets and approved therapies for mRCC.
  • To examine mechanisms of resistance to immunotherapy in mRCC.
  • To explore future directions and novel treatment strategies for mRCC management.

Main Methods:

  • Literature review of current immunotherapeutic targets and therapies for mRCC.
  • Analysis of mechanisms underlying primary refractoriness to immunotherapy.
  • Examination of emerging treatment strategies combining different mechanisms of action.

Main Results:

  • Combination immunotherapy and immunotherapy with targeted agents show improved outcomes compared to single-agent TKIs in mRCC.
  • ICIs are associated with durable responses in a subset of mRCC patients.
  • Primary refractoriness to immunotherapy remains a challenge in mRCC treatment.

Conclusions:

  • While immunotherapy has revolutionized mRCC treatment, challenges like primary resistance persist.
  • Novel strategies combining different mechanisms of action are crucial for improving response rates and survival.
  • Further research into immune escape pathways and combination therapies is needed to optimize mRCC management.
Keywords:
anti-CTLA-4anti-PD-1biomarkersimmunotherapymetastatic renal cell carcinomatargeted therapy

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.9K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
922
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.6K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
225